Potential mechanisms of resistance to cytarabine in AML patients

Leuk Res. 2002 Jul;26(7):621-9. doi: 10.1016/s0145-2126(01)00184-9.

Abstract

To determine whether the human equilibrative nucleoside transporter 1 (hENT1), deoxycytidine kinase (dCK), cytoplasmic 5'-nucleotidase (5NT), cytidine deaminase (CDD), topoisomerase I (TOPO I) and topoisomerase II alpha (TOPO II) are involved in clinical resistance to cytarabine (ara-C), we analyzed the level of expression of these parameters by reverse transcriptase polymerase chain reaction (rt-PCR), at diagnosis in the blast cells of 77 acute myeloid leukemia (AML) patients treated with ara-C, including 31 for whom samples were collected at first relapse. By univariate and/or multivariate analyses, patients with expression of 5NT or hENT1 deficiency at diagnosis had significantly shorter disease-free survival (DFS) and overall survival (OS). These results suggest that expression of 5NT and reduced hENT1 in leukemic blasts at diagnosis are correlated with clinical outcome and may play a role in resistance mechanisms to ara-C in patients with AML.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 5'-Nucleotidase / genetics
  • 5'-Nucleotidase / physiology
  • Acute Disease
  • Adult
  • Aged
  • Antigens, Neoplasm
  • Antimetabolites, Antineoplastic / pharmacology*
  • Antimetabolites, Antineoplastic / therapeutic use
  • Cytarabine / pharmacology*
  • Cytarabine / therapeutic use
  • Cytidine Deaminase / genetics
  • Cytidine Deaminase / physiology
  • DNA Topoisomerases, Type I / genetics
  • DNA Topoisomerases, Type I / physiology
  • DNA Topoisomerases, Type II / genetics
  • DNA Topoisomerases, Type II / physiology
  • DNA-Binding Proteins
  • Deoxycytidine Kinase / genetics
  • Deoxycytidine Kinase / physiology
  • Disease-Free Survival
  • Drug Resistance, Neoplasm / genetics
  • Drug Resistance, Neoplasm / physiology*
  • Equilibrative Nucleoside Transporter 1
  • Female
  • France / epidemiology
  • Humans
  • Leukemia, Myeloid / drug therapy
  • Leukemia, Myeloid / genetics
  • Leukemia, Myeloid / metabolism*
  • Leukemia, Myeloid / mortality
  • Life Tables
  • Male
  • Membrane Transport Proteins / genetics
  • Membrane Transport Proteins / physiology
  • Middle Aged
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / physiology*
  • Neoplastic Stem Cells / drug effects
  • Neoplastic Stem Cells / metabolism
  • Proportional Hazards Models
  • Retrospective Studies
  • Reverse Transcriptase Polymerase Chain Reaction
  • Survival Analysis

Substances

  • Antigens, Neoplasm
  • Antimetabolites, Antineoplastic
  • DNA-Binding Proteins
  • Equilibrative Nucleoside Transporter 1
  • Membrane Transport Proteins
  • Neoplasm Proteins
  • SLC29A1 protein, human
  • Cytarabine
  • Deoxycytidine Kinase
  • 5'-Nucleotidase
  • Cytidine Deaminase
  • DNA Topoisomerases, Type I
  • DNA Topoisomerases, Type II